These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 23965224)

  • 21. HER-2-positive breast cancer: hope beyond trastuzumab.
    Bartsch R; Wenzel C; Zielinski CC; Steger GG
    BioDrugs; 2007; 21(2):69-77. PubMed ID: 17402790
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Health care costs: how do we decide value? When do we decide? How do we particularize the decisions?
    Theriault RL
    Oncologist; 2012; 17(2):157-9. PubMed ID: 22302226
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Trastuzumab pharmacokinetics influenced by extent human epidermal growth factor receptor 2-positive tumor load.
    Oude Munnink TH; Dijkers EC; Netters SJ; Lub-de Hooge MN; Brouwers AH; Haasjes JG; Schröder CP; de Vries EG
    J Clin Oncol; 2010 Jul; 28(21):e355-6; author reply e357. PubMed ID: 20458048
    [No Abstract]   [Full Text] [Related]  

  • 24. Is there an ideal way to combine trastuzumab with chemotherapy?
    Gonzalez-Angulo AM; Hortobagyi GN
    J Clin Oncol; 2011 Dec; 29(34):4474-6. PubMed ID: 22042935
    [No Abstract]   [Full Text] [Related]  

  • 25. NICE guidance on trastuzumab emtansine for HER2-positive advanced breast cancer.
    Elsada A; Doss S; Robertson J; Adam EJ
    Lancet Oncol; 2016 Feb; 17(2):143-144. PubMed ID: 26703893
    [No Abstract]   [Full Text] [Related]  

  • 26. [HER2 testing in breast cancer].
    Yoshimura K
    Nihon Rinsho; 2007 Jun; 65 Suppl 6():275-80. PubMed ID: 17682167
    [No Abstract]   [Full Text] [Related]  

  • 27. Ado-trastuzumab emtansine (Kadcyla) for HER2-positive metastatic breast cancer.
    Med Lett Drugs Ther; 2013 Sep; 55(1425):75-6. PubMed ID: 24662957
    [No Abstract]   [Full Text] [Related]  

  • 28. Cardiotoxicity debated for anthracyclines and trastuzumab in breast cancer.
    Brower V
    J Natl Cancer Inst; 2013 Jun; 105(12):835-6. PubMed ID: 23733910
    [No Abstract]   [Full Text] [Related]  

  • 29. Economic evaluation and decision making: reimbursing trastuzumab in early-stage breast cancer.
    Simoens S
    Pharmacoeconomics; 2007; 25(3):181-5. PubMed ID: 17335304
    [No Abstract]   [Full Text] [Related]  

  • 30. Refining therapy for human epidermal growth factor receptor 2-positive breast cancer: T stands for trastuzumab, tumor size, and treatment strategy.
    Burstein HJ; Winer EP
    J Clin Oncol; 2009 Dec; 27(34):5671-3. PubMed ID: 19884535
    [No Abstract]   [Full Text] [Related]  

  • 31. Measurement of Domain-Specific HER2 (ERBB2) Expression May Classify Benefit From Trastuzumab in Breast Cancer.
    Carvajal-Hausdorf DE; Schalper KA; Pusztai L; Psyrri A; Kalogeras KT; Kotoula V; Fountzilas G; Rimm DL
    J Natl Cancer Inst; 2015 Aug; 107(8):. PubMed ID: 25991002
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Severe thrombocytopenia related to long-term trastuzumab exposure.
    Aguirre E; Taberner T; Luaña A; Morales S; Llombart A
    Tumori; 2013; 99(1):e1-2. PubMed ID: 23549016
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Trastuzumab after primary treatment for early stage HER2-positive breast cancer reduces recurrence.
    Dent R; Clemons M
    Cancer Treat Rev; 2006 Apr; 32(2):144-8. PubMed ID: 16517084
    [No Abstract]   [Full Text] [Related]  

  • 34. The efficacy of adjuvant trastuzumab in HER-2 positive breast cancer with axillary lymph node metastases according to the treatment duration.
    Sendur MA; Aksoy S; Ozdemir NY; Yazici O; Zengin N; Altundag K
    Curr Med Res Opin; 2014 Dec; 30(12):2535-42. PubMed ID: 25222762
    [TBL] [Abstract][Full Text] [Related]  

  • 35. HER-2 breast assay, linked to Herceptin, wins FDA's okay.
    Graziano C
    CAP Today; 1998 Oct; 12(10):1, 14-6. PubMed ID: 10187049
    [No Abstract]   [Full Text] [Related]  

  • 36. Herceptin (trastuzumab): adjuvant and neoadjuvant trials.
    Yaal-Hahoshen N; Safra T
    Isr Med Assoc J; 2006 Jun; 8(6):416-21. PubMed ID: 16833172
    [No Abstract]   [Full Text] [Related]  

  • 37. Could trastuzumab suppress hepatitis C virus in a patient with chronic hepatitis and breast cancer?
    Tamori A; Kawajiri H; Takashima T; Motoyama H; Morikawa H; Enomoto M; Hirakawa K; Kawada N
    Am J Gastroenterol; 2011 Oct; 106(10):1865-6. PubMed ID: 21979218
    [No Abstract]   [Full Text] [Related]  

  • 38. Cellular adaptive immune system plays a crucial role in trastuzumab clinical efficacy.
    Bellati F; Napoletano C; Ruscito I; Liberati M; Panici PB; Nuti M
    J Clin Oncol; 2010 Jul; 28(21):e369-70; author reply e371. PubMed ID: 20479394
    [No Abstract]   [Full Text] [Related]  

  • 39. Duration of adjuvant trastuzumab treatment in routine practice.
    Montserrat M; Leveque D; Barthelemy P; Bergerat JP
    Anticancer Res; 2012 Oct; 32(10):4585-8. PubMed ID: 23060590
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase II randomized study of trastuzumab emtansine versus trastuzumab plus docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer.
    Hurvitz SA; Dirix L; Kocsis J; Bianchi GV; Lu J; Vinholes J; Guardino E; Song C; Tong B; Ng V; Chu YW; Perez EA
    J Clin Oncol; 2013 Mar; 31(9):1157-63. PubMed ID: 23382472
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.